First new mycoprotein approved in EU amid concerns over slow regulatory timelines

The European Commission and EU member states have officially authorized a new mycoprotein ingredient for sale across the bloc, marking the first time a new mycoprotein has cleared the EU’s Novel Foods regulation since the framework was established in the late 1990s.

Developed by Dutch startup The Protein Brewery, the ingredient, known as Fermotein, is produced via biomass fermentation. While existing mycoproteins on the European market rely on other fungal strains, this one utilizes the filamentous fungus R. pusillus. Though previously used in cheesemaking enzymes and traditional fermented products, this authorization allows the fungus to be marketed as a primary ingredient. Initial commercial applications within the EU are expected to target plant-based dairy alternatives, baked goods, and specialized sports nutrition.

Proponents of the ingredient point to its potential nutritional and environmental benefits. A lifecycle assessment commissioned by the manufacturer and conducted by Wageningen University and Research stated that Fermotein utilizes significantly less land and water per kilogram of protein than conventional dairy agriculture. Supporters argue that such localized production methods could help reduce the EU's heavy reliance on external agricultural inputs, given that the EU’s agrifood sector currently imports roughly 66% of its animal feed.

However, the authorization has also highlighted ongoing friction within Europe’s regulatory framework. The approval process spanned six years from the initial submission to final clearance. This timeline lags considerably behind other global markets; both the United States and Singapore granted regulatory approval for the same ingredient more than a year ago.

This regulatory disparity has drawn criticism from industry analysts and alternative protein advocates, who argue that protracted approval windows stifle innovation, delay infrastructure investment, and may incentivize European startups to relocate or scale their operations abroad.

To address these systemic delays without compromising safety standards, industry groups have called for structural updates at the European Food Safety Authority (EFSA). Proposed measures include expanded agency capacity, clearer pre-submission guidelines to improve initial application quality, and the introduction of "regulatory sandboxes" to help officials assess unfamiliar technologies in controlled settings.

While the market entry of Fermotein establishes a new regulatory precedent, it underscores the broader challenge facing Brussels: balancing the EU's stringent, world-leading food safety standards with the commercial realities and timelines of global food technology innovation.

Source:

GFI Europe